89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer-Reference-Cited by-同舟云学术

89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer

Published:2014-08-21 Issue:11 Volume:41 Page:2093-2105
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Pandit-Taskar Neeta,O’Donoghue Joseph A.,Beylergil Volkan,Lyashchenko Serge,Ruan Shutian,Solomon Stephen B.,Durack Jeremy C.,Carrasquillo Jorge A.,Lefkowitz Robert A.,Gonen Mithat,Lewis Jason S.,Holland Jason P.,Cheal Sarah M.,Reuter Victor E.,Osborne Joseph R.,Loda Massimo F.,Smith-Jones Peter M.,Weber Wolfgang A.,Bander Neil H.,Scher Howard I.,Morris Michael J.,Larson Steven M.

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-014-2830-7.pdf

Reference46 articles.

1. Kiess AP, Cho SY, Pomper MG. Translational molecular imaging of prostate cancer. Curr Radiol Rep 2013;1(3):216–26.

2. Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol 2013;40(3):375–92.

3. Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med 2013;54(5):699–706.

4. Schuster DM, Nieh PT, Jani AB, Amzat R, Bowman FD, Halkar RK, et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 2014;191(5):1446–53.

5. Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Bemdsen S, Grievink-de Ligt CH, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2011;38(7):1257–66.

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial;The Lancet Oncology;2024-08

2. A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO);2024-06-02

3. Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?;Pharmaceuticals;2024-04-16

4. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer;Clinical Cancer Research;2024-04-09

5. [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis;Cancer Imaging;2024-02-22